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Aim: To evaluate the distribution of intramyocellular lipids (IMCLs) and
extramyocellular lipids (EMCLs) as well as total fat content in abdominal skeletal mus-
cle by magnetic resonance imaging (MRI) using a dedicated segmentation algorithm in
subjects with type 2 diabetes (T2D), prediabetes and normoglycaemic controls.
Materials and Methods: Subjects from a population-based cohort were classified
with T2D, prediabetes or as normoglycaemic controls. Total myosteatosis, IMCLs and
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EMCLs were quantified by multiecho Dixon MRI as proton-density fat-fraction (in %)
in abdominal skeletal muscle.
Results: Among 337 included subjects (median age 56.0 [IQR: 49.0-64.0] years,
56.4% males, median body mass index [BMI]: 27.2 kg/m2), 129 (38.3%) were classi-
fied with an impaired glucose metabolism (T2D: 49 [14.5%]; prediabetes: 80 [23.7%]).
IMCLs were significantly higher than EMCLs in subjects without obesity (5.7% [IQR:
4.8%-7.0%] vs. 4.1% [IQR: 2.7%-5.8%], P < .001), whereas the amounts of IMCLs and
EMCLs were shown to be equal and significantly higher in subjects with obesity (both
6.7%, P < .001). Subjects with prediabetes and T2D had significantly higher amounts
of IMCLs and EMCLs compared with normoglycaemic controls (P < .001). In
univariable analysis, prediabetes and T2D were significantly associated with both
IMCLs (prediabetes: β: 0.76, 95% CI: 0.28-1.24, P = .002; T2D: β: 1.56, 95% CI:
0.66-2.47, P < .001) and EMCLs (prediabetes: β: 1.54, 95% CI: 0.56-2.51, P = .002;
T2D: β: 2.15, 95% CI: 1.33-2.96, P < .001). After adjustment for age and gender, the
association of IMCLs with prediabetes attenuated (P = 0.06), whereas for T2D, both
IMCLs and EMCLs remained significantly and positively associated (P < .02).
Conclusion: There are significant differences in the amount and distribution ratio of
IMCLs and EMCLs between subjects with T2D, prediabetes and normoglycaemic
controls. Therefore, these patterns of intramuscular fat distribution by MRI might
serve as imaging biomarkers in both normal and impaired glucose metabolism.
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1 | INTRODUCTION
Insulin resistance is considered the major feature in the pathophysiology
of type 2 diabetes (T2D).1 In general, lipids such as triglycerides interfere
with peripheral insulin signalling by competing with glucose for energy
production.2 Thereby, increased levels of circulating plasma lipids inhibit
insulin-stimulated, peripheral glucose metabolism, consistent with an
increased peripheral insulin resistance.3,4 However, not only higher
levels of circulating plasma lipids but also increased ectopic lipid deposits
within peripheral organs are considered causal factors in the develop-
ment of insulin resistance.3,5 Because skeletal muscle is the primary
organ accounting for the whole-body insulin-stimulated glucose dis-
posal, peripheral insulin sensitivity mainly depends on glucose utilization
in skeletal muscle tissue. Thus, even minor changes in skeletal muscle
composition regarding fat content and lipid distribution may be key fac-
tors contributing to the pathogenesis of insulin resistance and T2D.6,7
Intramuscular fat may be deposited in two distinct compartments,
either as intramyocellular lipids (IMCLs) accumulated in the cytoplasm
of myocytes or as extramyocellular lipids (EMCLs) in interstitial,
intramyofascial adipocytes. They differ essentially regarding their
chemical reactivity, with EMCLs being metabolically rather inert and
IMCLs, by contrast, being characterized by a rapid cycle of storage,
mobilization and usage as a fast available source of energy.8,9 Recent
data suggest a correlation of insulin resistance and IMCLs rather than
EMCLs in subjects with normoglycaemia and diabetes as well as in
subjects with and without obesity.10 Furthermore, the amount of
IMCLs has been described as a promising predictor and potential
marker for muscular insulin resistance.7,11,12
In the past, reliable quantification of skeletal muscle fat content
was only possible ex vivo by invasive techniques (histopathology).
However, non-invasive methodologies using magnetic resonance
(MR), such as single-voxel proton-MR spectroscopy,13 or T2*-
corrected, multiecho 3D-gradient-echo Dixon-based methods, have
recently been established.14,15 These MR-based approaches provide
reliable quantification of skeletal muscle fat content, offer the ability
to distinguish between IMCLs and EMCLs in vivo, and allow for the
simultaneous evaluation of further imaging biomarkers of skeletal
muscle, such as mass. We hypothesize that MR imaging (MRI)-
determined differences in total fat content and lipid distribution
within skeletal muscle tissue may serve as imaging biomarkers
reflecting different states of impaired glucose metabolism.
In this context, we evaluated the distribution of IMCLs and
EMCLs as well as total fat content in abdominal skeletal muscle by
MRI using a dedicated segmentation algorithm in subjects with T2D,
prediabetes and normoglycaemic controls from a population-based,
cross-sectional cohort. Furthermore, we aimed to determine the dis-
tribution of IMCLs and EMCLs in these three population strata with
different cardiometabolic risk factors.
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2 | MATERIALS AND METHODS
2.1 | Study design and population
Subjects were derived from the KORA-FF4 study (2013-2014,
n = 2279), the second follow-up study of a population-based survey
within the Cooperative Health Research in the Region of Augsburg
(KORA) survey in southern Germany. The study was approved by
the ethics committee of the Bavarian Chamber of Physicians,
Munich, Germany, and the local institutional review board of the
Ludwig-Maximilians Universität München, Munich, Germany (EC no.
06068). Written informed consent was obtained from all partici-
pants. The design of the KORA studies has been described in detail
previously.16 In brief, all participants underwent a comprehensive
health assessment with standardized interviews and physical exami-
nations. Furthermore, 400 eligible subjects underwent whole-body
MRI according to previously described inclusion and exclusion
criteria.16
2.2 | Glycaemic status
To determine the glycaemic status of the participants, one 75-g oral
glucose tolerance test (OGTT) was performed for all subjects who had
not yet been diagnosed with diabetes. According to the World Health
Organization (WHO) OGTT definition, subjects were classified with an
impaired glucose metabolism either with established T2D or prediabe-
tes (impaired glucose tolerance and/or impaired fasting glucose: 2-hour
plasma glucose following a 75-g OGTT ≥ 7.8 mmol/L and/or fasting
plasma glucose [FPG] ≥ 5.6 mmol/L), and as healthy (normoglycaemic)
controls (OGTT < 7.8 mmol/L and/or FPG < 5.6 mmol/L).17 Homeo-
static model assessment of insulin resistance (HOMA-IR) was calculated
for all subjects without antihyperglycaemic medication (with glucose in
mass units: mg/dL).
2.3 | Anthropometric measurements and obesity
Body mass index (BMI) was calculated as weight (kg) divided by body
height squared (m2), with body weight and height both measured at
the study centre. Waist circumference was measured at the smallest
abdominal circumference or, in subjects with obesity, in the midpoint
of the lowest rib and the upper margin of the iliac crest. Hip circum-
ference was determined at the most protruding part of the hips to the
nearest 1 mm. Obesity was defined according to the WHO definition
with a BMI of 30 kg/m2 as the cut-off value.18
2.4 | MRI protocol and data acquisition
MRI examinations were performed in supine position on a 3-Tesla
Magnetom Skyra (Siemens Healthineers, Erlangen, Germany) using an
18-channel body surface coil in combination with a table-mounted
spine matrix coil. The complete imaging protocol as well as technical
specificities have been described in detail elsewhere.16
For the segmentation of abdominal skeletal muscle, a T2*-
corrected, multiecho 3D-gradient-echo Dixon-based sequence (multi-
echo Dixon) of the abdomen with the following parameters was used:
time to repetition (TR): 8.90 ms; time to echo (TE): 1.23, 2.46, 3.69,
4.92, 6.15 and 7.38 ms; flip angle 4; readout echo bandwidth
1080 Hz/pixel; matrix 256 x 256; slice thickness 4 mm. Data were
acquired during a breath-hold of 15 seconds. The postprocessing
algorithm using the software MR LiverLab (version VD13; Siemens
Healthineers, Cary, NC, USA) automatically calculated water- and fat-
only images as DICOM-files from the original data of the six echoes.
The obtained fat signal-fraction maps are based on the signal ratio of
fat to the summed signal of water and fat (proton-density fat-fraction
[PDFF]) and are corrected for the confounding effects of T2*-decay,
quantitatively coding the mean PDFF in degrees of grey values of
each voxel (1 intensity value = 0.1% fat content).14
Furthermore, coronal two-point Dixon gradient-echo sequences
(TR 4.06 ms, TE 1.26 and 2.49 ms, flip angle 9, slice thickness
1.7 mm, isotropic in-plane resolution 1.7 mm) were used for the iden-
tification of level L3 vertebra on axial slices by cross-reference.
2.5 | MR image analysis and skeletal muscle
segmentation
The DICOM files were implemented into the commercially available soft-
ware, OsiriX (version 8.5.1; Pixmeo SARL, Bernex, Switzerland), on a ded-
icated, offline workstation. Two trained independent observers blinded
to any covariates of the subjects performed image analysis and abdomi-
nal skeletal muscle segmentation. Details of the applied segmentation
approach have been described before.15 In brief, each abdominal muscle
compartment (both the right and left psoas major muscle, quadratus lum-
borum muscle, autochthonous back muscles and rectus abdominis mus-
cle) was manually segmented according to standardized, anatomical
landmarks on one single, axial slice at the level of the lower endplate of
the L3 vertebra. If the L3 vertebra was not imaged, the most caudal pos-
sible axial slice was selected. Subjects with significant image artifacts at
all levels were excluded from the analysis. If artifacts were limited to level
L3, the next possible cranial slice without artifacts was selected.
Interobserver and intraobserver reproducibility were assessed in a
subset of 50 randomly selected subjects, being excellent for all included
muscle compartments with only minor absolute and relative differences
(intraclass correlation coefficient (ICC) 0.94-1.0, 0.2% ± 0.5%, 2.6%
± 6.4%; ICC 0.96-1.0, 0.0% ± 0.4%, 0.4% ± 3.8%, respectively).15
2.5.1 | Total, intramyocellular and extramyocellular
fat content
All muscle compartments were segmented manually as described
before using dedicated and standardized anatomical landmarks.15
Total muscle fat content was determined as mean PDFF (in %) within
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each muscle compartment. It includes intramyocellular and
intermyocellular-intrafascial lipids and adipose tissue and excludes
surrounding, extramyocellular-extramyofascial adipose tissue.
IMCLs were quantified by postprocessing the segmented muscle
compartments using a semiautomatic, in-house application (Matlab_
R2017a; MathWorks, MA, USA) (Figure S1). This algorithm is based
on the presumption that myocytes with a high amount of intra-
myocellular lipids do not feature an intensity value greater than
approximately 200 (corresponding to 20% fat content) in PDFF maps
and that every voxel with an intensity value greater than 200 addition-
ally contains extramyocellular adipose tissue. Thus, an approved
threshold value of 200 was set to quantify those voxels that comprise
only myocytes with IMCLs excluding ECMLs.19 ECMLs were consecu-
tively calculated as the difference of total abdominal skeletal muscle
fat content (threshold value of 1000, corresponding to up to 100% fat
content) and ICMLs, comprising predominantly extramyocellular-
intramuscular fatty septa and adipose tissue within the muscle fascia.
2.5.2 | Visceral and subcutaneous adipose tissue;
hepatic fat fraction
Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) as
abdominal adipose tissue compartments were segmented and quanti-
fied (in cm2) by a semiautomated algorithm based on fuzzy clustering
on one axial slice at the level of the umbilicus. Therefore, axial slices
with a slice thickness of 5 mm were reconstructed based on 3D VIBE-
Dixon sequences, which were assessed in the coronal direction.20,21
Hepatic fat fraction (HFF) was determined using a T2*-corrected,
multiecho Dixon sequence with regions of interest being placed in the
right and left liver lobes (segments 8 and 2). HFF was then calculated
as the average of the right and left lobe measurements.16
2.6 | Other covariates
Hypertension was determined as a systolic blood pressure of 140 mmHg
or higher and/or diastolic blood pressure of 90 mmHg or higher or cur-
rent intake of antihypertensive medication (given that the participant
was aware of being hypertensive).22,23 Regarding physical activity, sub-
jects were categorized as physically active (regular physical activity ≥1 h/
wk) or physically inactive (irregular physical activity <1 h/wk, almost no
and no physical activity). Routine intake of lipid-lowering medication,
non-steroidal anti-inflammatory drugs, and oral antihyperglycaemic as
well as antihypertensive agents, was similarly evaluated by self-report.
Smoking status was classified by self-report as never-smoker, ex-smoker
and current (regular or sporadic) smoker.
2.7 | Statistical analysis
Baseline characteristics of the study population are presented as
median with first and third quartile (interquartile range [IQR]) for
continuous variables and absolute counts with percentages for cate-
gorical variables. Differences in median values or counts between sub-
jects with diabetes, prediabetes and healthy controls were assessed
by Kruskal-Wallis’ equality-of-populations rank test (quantitative data)
or χ2-test (qualitative data). Correlations of IMCLs and EMCLs with
cardiometabolic risk factors were evaluated by scatter plots and
Spearmanʼs rho correlation coefficients, and differences according to
glycaemic status were evaluated by Kruskal-Wallis test. Associations
of IMCLs and EMCLs with cardiometabolic risk factors were deter-
mined by median regression adjusted for age and gender. Statistical
significance was indicated by P values of less than .05. Statistical anal-
ysis was performed using R version 3.4.1 (R Core Team; www.r-
project.org, 2017).
3 | RESULTS
3.1 | Study population
Among 400 subjects who underwent whole-body MRI, 63 subjects
(15.8%) were excluded because of insufficient image quality, incom-
plete MRI datasets of one of the sequences included, or because of
missing values in any of the covariates. Thus, the study cohort con-
sisted of 337 subjects (median 56.0 [IQR: 49.0-64.0] years, 56.4%
males, median BMI: 27.2 kg/m2). Demographics and detailed charac-
teristics of the study population are provided in Table S1.
Overall, 129 subjects (38.3%) were classified with an impaired
glucose metabolism (established T2D: 49 subjects [14.5%] and predia-
betes: 80 subjects [23.7%], respectively). These subjects with
prediabetes and T2D featured a more distinct cardiometabolic risk
profile, being older and more probably male, having a higher preva-
lence of obesity, hypertension and dyslipidaemic changes of blood
lipids, as well as higher amounts of VAT and SAT. Furthermore, partic-
ipants with impaired glucose metabolism were significantly less physi-
cally active (all P < .002; Table S1).
3.2 | Total, intramyocellular and extramyocellular
fat content
Detailed results of measurements of total, intramyocellular and
extramyocellular fat content are provided in Table 1. Median total fat
content in all muscle compartments was 9.6% (IQR: 7.7%-12.7%) in
normal-weight subjects and 13.4% (IQR: 10.4%-16.1%) in subjects
with obesity (P < .001). In subjects with and without obesity, total fat
content, IMCLs and EMCLs were lowest in the quadratus lumborum
muscle (normal weight: total fat content 5.4% [IQR: 3.7%-7.5%],
IMCLs 3.8% [IQR: 2.9%-4.9%] and EMCLs 1.4% [IQR: 0.4%-2.7%];
obesity: total fat content 6.6% [IQR: 5.1%-9.2%], IMCLs 4.2% [IQR:
3.3%-5.2%] and EMCLs 2.4% [IQR: 1.0%-3.9%]; P < .001, respectively)
and highest in the autochthonous back muscles (normal weight: total
fat content 14.0% [IQR: 9.7%-18.0%], IMCLs 7.0% [IQR: 5.7%-8.7%]
and EMCLs 6.4% [IQR: 3.9%-9.3%]; obesity: total fat content 17.7%
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[IQR: 13.0%-22.5%], IMCLs 8.6% [IQR: 6.1%-10.5%] and EMCLs 7.4%
[IQR: 5.0%-15.0%]; P < .001, respectively).
In general, IMCLs were significantly higher than EMCLs in
normal-weight subjects (IMCLs: 5.7% vs. EMCLs: 4.1%), whereas
the amounts of IMCLs and EMCLs were shown to be equal and
significantly higher in subjects with obesity (6.7% for both
IMCLs and EMCLs) (P < .001). Also, both subjects with and with-
out obesity with impaired glucose metabolism had significantly
higher amounts of IMCLs and EMCLs compared with normoglycaemic
controls in all muscle compartments (P < .001) (Table 1). In general,
subjects with obesity and with T2D had the highest amounts of total
myosteatosis, IMCLs and EMCLs, whereas normoglycaemic and
normal-weight subjects had the lowest amounts of intramuscular fat
(Figures 1 and S1).
3.3 | Correlations and predictors of
intramyocellular and extramyocellular fat content
Results of univariable analysis of correlations between subjectsʼ
demographics and characteristics with IMCLs and EMCLs are shown
in Table 2. In univariable analysis, cardiometabolic risk factors, such as
age, measures of obesity (BMI, waist and hip circumference, VAT and
SAT) and hypertension, were significantly and positively correlated
F IGURE 1 Total (A), intramyocellular
(B) and extramyocellular fat content (C) in
abdominal skeletal muscle in non-obese
and obese subjects with type 2 diabetes
(T2D), prediabetes and normal glucose
tolerance. EMCL, extramyocellular lipids;
IMCL, intramyocellular lipids
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with the amounts of IMCLs and EMCLs (all P < .001) (Figure 2). A neg-
ative correlation of gender and intramuscular fat was observed for EMCLs
but not for IMCLs (P = .01 and P = .28, respectively). Regarding
dyslipidaemic changes of circulating blood lipids, elevated triglyceride
levels and total cholesterol were significantly correlated with IMCLs (and
not with EMCLs) (P < .02). Furthermore, regular intake of lipid-lowering
medication and EMCLs, as well as of non-steroidal anti-inflammatory
drugs and both IMCLs and EMCLs, were shown to be significantly corre-
lated (P < .03). By contrast, there was a significant but negative correlation
of both IMCLs aswell as EMCLswith physical activity (Figure 2). Consider-
ing all muscle compartments, diabetes durationwas not significantly corre-
lated with total muscle fat content (Spearmanʼs rho = 0.03, P = .88),
IMCL (rho= 0.02, P= .9) or EMCL (rho=0.04, P= .83).
Regarding impaired glucose metabolism, elevated HbA1c and glu-
cose levels, and especially the two pathological conditions, predia-
betes and established T2D itself, were shown to be significantly
and positively associated with the amounts of IMCLs and EMCLs in
unadjusted analysis (P < .03). However, after adjustment for age
and gender, the association of IMCL with prediabetes attenuated
(P = .06), whereas for established T2D, both IMCLs and EMCLs
remained significantly and positively associated (P < .02). Further-
more, obesity was significantly and positively associated with
IMCLs and EMCLs in both unadjusted and adjusted analysis
(P > .002) (Table 3A). Analysis of interaction effects between
glycaemic status and obesity revealed significant associations of
obesity with both IMCLs and EMCLs in subjects with normal
TABLE 2 Univariable analysis of associations between demographics and cardiometabolic risk factors with IMCLs and EMCLs
Predictor
Estimate (beta) 95% CI P value
IMCL EMCL IMCL EMCL IMCL EMCL
Age (y) 0.74 1.14 [0.54, 0.94] [0.78, 1.50] <0.001 <0.001
Gender (male) 0.26 1.23 [0.74, 0.21] [2.12, 0.34] 0.28 0.01
BMI (kg/m2) 0.63 1.08 [0.40, 0.87] [0.78, 1.38] <0.001 <0.001
Obesity 1.02 2.59 [0.52, 1.53] [1.61, 3.58] <0.001 <0.001
Waist circumference (cm) 0.60 0.95 [0.40, 0.80] [0.70, 1.20] <0.001 <0.001
Hip circumference (cm) 0.47 0.97 [0.27, 0.66] [0.60, 1.34] <0.001 <0.001
Hypertension 1.05 1.80 [0.50, 1.59] [1.00, 2.59] <0.001 <0.001
Systolic blood pressure (mmHg) 0.46 0.57 [0.24, 0.68] [0.29, 0.85] <0.001 <0.001
Diastolic blood pressure (mmHg) 0.12 0.23 [0.10, 0.33] [0.12, 0.58] 0.283 0.201
Diabetes status
Healthy control Ref Ref Ref Ref Ref Ref
Prediabetes 0.76 1.54 [0.28, 1.24] [0.56, 2.51] 0.002 0.002
T2D 1.56 2.15 [0.66, 2.47] [1.33, 2.96] <0.001 <0.001
Physically active (regularly, ≥1 h/wk) 0.71 0.82 [1.34, 0.08] [1.61, 0.03] 0.03 0.04
HbA1c (%) 0.57 0.77 [0.07, 1.08] [0.07, 1.47] 0.03 0.03
Fasting serum glucose (mg/dL) 0.53 0.68 [0.18, 0.88] [0.30, 1.06] 0.003 <0.001
Triglyceride levels (mg/dL) 0.39 0.27 [0.14, 0.63] [0.00, 0.54] 0.002 0.06
Total cholesterol (mg/dL) 0.22 0.22 [0.04, 0.40] [0.08, 0.51] 0.02 0.15
HDL (mg/dL) 0.02 0.07 [0.24, 0.19] [0.46, 0.33] 0.82 0.74
LDL (mg/dL) 0.13 0.03 [0.05, 0.30] [0.35, 0.41] 0.15 0.88
Medication
Lipid-lowering medication 0.91 2.04 [0.06, 1.88] [0.76, 3.31] 0.07 0.002
Non-steroidal anti-inflammatory drugs 2.15 2.47 [1.63, 2.67] [0.32, 4.62] <0.001 0.03
Oral antihyperglycaemic agents 1.98 2.14 [1.16, 2.80] [0.88, 3.40] <0.001 <0.001
Oral antihypertensive agents 0.99 2.29 [0.37, 1.61] [1.18, 3.39] 0.002 <0.001
Hepatic fat fraction (%) 0.53 0.67 [0.19, 0.87] [0.15, 1.19] 0.003 0.01
VAT (cm2) 0.75 0.92 [0.43, 1.06] [0.57, 1.27] <0.001 <0.001
SAT (cm2) 0.56 1.22 [0.38, 0.73] [0.84, 1.60] <0.001 <0.001
Note: β-coefficients derived from median regression. Continuous predictors were standardized before analysis.
Abbreviations: BMI, body mass index; CI, confidence interval; EMCL, extramyocellular lipids; hypertension, RRsys ≥ 140 mmHg and/or RRdia ≥ 90 mmHg, or
current intake of antihypertensivemedication; IMCL, intramyocellular lipids; obesity, BMI > 30 kg/m2; SAT, subcutaneous adipose tissue; T2D, type 2
diabetes; VAT, visceral adipose tissue.
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glucose tolerance and T2D (P < 0.04), but not in subjects with pre-
diabetes (Table 3B).
4 | DISCUSSION
Disruption of muscular glucose and lipid homeostasis is assumed to
be crucial in the development of prediabetes and T2D. Thereby,
changes in skeletal muscle fat content as well as lipid distribution
within muscle tissue are expected to be linked to peripheral insulin
sensitivity. Recent data suggested a correlation of insulin resistance
and myosteatosis in subjects with normoglycaemia and diabetes as
well as in subjects with and without obesity. However, data on mus-
cular fat content and lipid distribution patterns within abdominal skel-
etal muscle in a population-based cohort are missing to date. Our
results indicate that there are significant differences in total muscle
fat content and muscular lipid distribution between subjects of normal
weight and subjects with obesity with T2D, prediabetes and
normoglycaemia, which may be assessed non-invasively by MRI. Pat-
terns of intramuscular fat distribution and insulin sensitivity-related
differences as assessed by MRI show potential as feasible imaging bio-
markers in impaired glucose metabolism and also other metabolic
diseases.
IMCLs and EMCLs represent ectopic lipid storages in two
different compartments within muscle tissue. On the one hand, IMCLs
constitute an important, fast available source of energy during muscle
contraction and regeneration.24 On the other hand, EMCLs represent
a rather long-term storage, which is built up in cases of excess fat
availability.8,9 IMCLs have recently been implicated in the pathogene-
sis of skeletal muscle insulin resistance.10 However, elevated amounts
of IMCLs also occur in trained athletes25 and in other cases of
enhanced fat oxidation. Thereby, IMCLs do not adversely affect mus-
cular insulin sensitivity but exhibit an essential function for skeletal
muscle metabolism and physical capability.26 In agreement with that,
normal-weight subjects (who were also significantly more physically
active) showed higher amounts of IMCLs compared with EMCLs in all
F IGURE 2 Correlations and distributions of intramyocellular and extramyocellular fat content with age (A), body mass index (BMI) (B), visceral
adipose tissue (VAT) (C), physical activity (inactive: irregular physical activity <1 h/wk, almost no and no physical activity; active: regular physical
activity ≥1 h/wk) (D), fasting insulin (E) and fasting glucose (F); grey = normoglycaemia; blue = prediabetes; red = diabetes (no oral
antihyperglycaemic medication, ●oral antihyperglycaemic medication). EMCL, extramyocellular lipids; IMCL, intramyocellular lipids
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muscle compartments, whereas subjects with obesity had both higher
amounts of IMCLs and EMCLs in our study. These different patterns
of muscular lipid distribution may be feasible imaging markers in phys-
iological as well as in impaired skeletal muscle metabolism.
Previously published results by Jacob et al. showed that IMCLs
were significantly higher in insulin-resistant individuals compared with
insulin-sensitive subjects. Thus, they concluded that elevated IMCLs
may represent an early abnormality in the pathogenesis of muscular
insulin resistance.12 In our cohort, we also found a significant associa-
tion of IMCLs, in both prediabetes and T2D, in unadjusted analysis.
However, after adjusting for age and gender, the association of IMCLs
and prediabetes was attenuated. One explanation for this discrepancy,
in comparison with the results from Jacob et al., may be the
complexity of skeletal muscle metabolic dysfunction in metabolic
syndrome, specifically in the setting of co-morbidities of diabetes,
obesity and other cardiometabolic diseases. In our cohort, subjects
with impaired glucose tolerance also showed a significantly more
distinct cardiometabolic risk profile. Furthermore, and in contrast
to the study conducted by Jacob et al., different glycaemic status
groups were not matched for cardiometabolic risk factors. Because
skeletal muscle lipid and glucose metabolism are dynamically
linked, an increased BMI as a general measure for obesity may
thereby confound the association of IMCLs and muscular insulin
resistance. These results may further support the theory of mutual
reactions of dyslipidaemia and dysglycaemia, resulting in both
hyperglycaemic and hyperlipidaemic muscle fat infiltration. Still,
TABLE 3 (A) Multivariable associations between the glycaemic status and IMCLs/EMCLs and (B) interactive effects of glycaemic status and
obesity
Estimate (beta) 95% CI P value




Normoglycaemia Ref Ref Ref Ref Ref Ref
Prediabetes 0.76 1.54 [0.28, 1.24] [0.56, 2.51] .002 .002
T2D 1.56 2.15 [0.66, 2.47] [1.33, 2.96] <.001 <.001
Model 2
Normal weight Ref Ref Ref Ref Ref Ref
Obesity 1.02 2.59 [0.52, 1.53] [1.61, 3.58] <.001 <.001
Adjusted for age and gender
Model 1
Normoglycaemia Ref Ref Ref Ref Ref Ref
Prediabetes 0.49 1.02 [0.01, 0.99] [0.42, 1.63] .06 .001
T2D 1.31 1.71 [0.25, 2.38] [0.92, 2.50] .02 <.001
Model 2
Normal weight Ref Ref Ref Ref Ref Ref
Obesity 0.84 1.63 [0.32, 1.35] [0.88, 2.37] .002 <.001
(B)
Normoglycaemia
Normal weight Ref Ref Ref Ref Ref Ref
Obesity 0.92 1.47 [0.33, 1.52] [0.10, 2.84] .002 .04
Prediabetes
Normal weight 0.84 0.88 [0.22, 1.46] [0.05, 1.80] .008 .06
Obesity 0.37 1.47 [0.32, 1.06] [0.11, 3.06] .29 .07
T2D
Normal weight 0.79 1.15 [0.54, 2.11] [0.00, 2.31] .25 .05
Obese 1.82 2.59 [0.62, 3.03] [1.43, 3.75] .003 <.001
Note: β-coefficients with 95% CIs derived from median regression (A) and β-coefficients with 95% CIs derived from median regression, adjusted for age
and gender (B).
Abbreviations: CI, confidence interval; EMCL, extramyocellular lipids; IMCL, intramyocellular lipids; bbesity: body mass index > 30 kg/m2; T2D, type 2
diabetes.
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whether IMCLs are causally linked to insulin resistance is a matter
of considerable debate and should be addressed in further, large-
scale studies.
Because obesity leads to significant fat maldistribution within the
human body, ectopic lipid deposits, for example in the liver or in skele-
tal muscle, have recently moved into focus. Subjects with obesity in
our study were not only characterized by significantly higher amounts
of total muscle fat content and IMCLs, but also EMCLs in all muscle
compartments and in all three glycaemic status groups compared with
the normal-weight groups. Also, different measures of obesity and
especially elevated amounts of VAT and SAT or hepatic fat fraction
(as other cardiometabolic imaging biomarkers) were significantly
associated with both IMCLs and EMCLs. Furthermore, increased
peripheral lipid availability (e.g. elevated plasma triglyceride or cho-
lesterol levels) was shown to be significantly associated with IMCLs.
These correlations further highlight the complex relationship of glu-
cose and lipids in different metabolic co-morbidities (especially T2D
and obesity). Evaluating skeletal muscle biomarkers by MRI, as
assessed in the current study, may therefore help to further charac-
terize muscular changes in metabolic disorders and also elucidate
the relationship between insulin resistance and intramyocellular fat
components.
Some limitations of this study should be taken into account. First,
we did not compare the results of muscular fat quantification by MRI
with histopathology, which is seen as the current gold standard. How-
ever, former studies have shown the validity and reproducibility of
the multiecho Dixon-based method used in this study.15 Second, as
mentioned above, the three glycaemic status groups were not fully
matched with respect to age, gender and measures of obesity. How-
ever, while multivariable analysis was used to adjust for potential con-
founders, our findings are limited by a comparatively small sample size
(second follow-up study) from a southern German population and the
cross-sectional study design, and thus require confirmation in larger
and longitudinal cohort studies, for example, the German National
Cohort MRI study.27,28
In conclusion, we found significant differences in total muscle fat
content, IMCLs and EMCLs between subjects with normal weight and
obesity with T2D, prediabetes and normoglycaemic controls that
may be assessed non-invasively by MRI. Different patterns of intra-
muscular fat distribution may therefore be regarded as feasible imag-
ing biomarkers in impaired glucose metabolism and other metabolic
diseases and may further elucidate a ‘muscular phenotype’ associated
with an increased cardiometabolic risk. This might enable ‘muscular
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